Peter Dechent
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peter Dechent has a total of 219 co-authors. Here are the top co-authors by number of shared publications:
- Jens Wiltfang
Universitätsmedizin Göttingen
8 shared publications - Josef Priller
Department of Psychiatry and Psychotherapy, Charité – Universitätsmedizin Berlin, Berlin, Germany
7 shared publications - Stefan Teipel
German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany
7 shared publications - Anja Schneider
Department of Old Age Psychiatry and Cognitive Disorders, University Hospital Bonn, Bonn, Germany
6 shared publications - Annika Spottke
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
6 shared publications - Björn Hendrik Schott
Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, Goettingen, Germany
6 shared publications
Latest Publications
- Open Access
MRI-derived brain aging trajectories across the Alzheimer’s continuum: links to cognition, pathology and lifestyle risk factors
Background: The brain age gap (BAG), the difference between neuroimaging-predicted and chronological age, captures inter-individual variation in brain aging. Although sensitive to Alzheimer’s disease (AD) pathology, its longitudinal patterns across the clinical AD continuum and prognostic relevance remain unclear. Methods: 577 participants from the DELCODE cohort (>2,100 MRI scans) were analysed: healthy controls individuals (HC, N=202), and patients with subjective cognitive decline (SCD, N=248), mild cognitive impairment (N=93), and AD dementia (N=34). All underwent structural MRI, amyloid (Aβ 42/40 ) and phosphorylated tau181 assessment, and lifestyle-related dementia risk profiling (LIBRA). BAG was derived using brainageR. Associations with baseline cognition, cognitive decline, and clinical progression (up to eight years) were examined using mixed-effects and Cox models. Mediation analyses tested whether BAG accounted for LIBRA-cognition associations. Biomarker-related and clinical findings were replicated in ADNI (N=461). Findings: BAG showed excellent short-term reliability, increased stepwise across the clinical spectrum and was elevated in amyloid-positive SCD, but not in asymptomatic amyloid-positive HC. Longitudinal BAG increases were strongest in amyloid- and tau-positive participants (Aβ+T+). Higher BAG was associated with poorer baseline cognition and predicted cognitive decline, with strongest effects in Aβ+T+. All main findings replicated in ADNI. BAG was associated with LIBRA only in biomarker-negative participants and partly mediated associations with cognitive outcomes in DELCODE. Interpretation: BAG is a reliable non-invasive marker of structural brain health sensitive to AD pathology and to modifiable AD risk. Detectable divergence prior to objective cognitive impairment supports its relevance for early risk stratification and prevention-oriented research. Funding: Helmholtz AI Cooperation Unit (ZT-I-PF-5-163).
Open AccessMRI-derived brain aging trajectories across the Alzheimer’s continuum: links to cognition, pathology and lifestyle risk factors
Background: The brain age gap (BAG), the difference between neuroimaging-predicted and chronological age, captures inter-individual variation in brain aging. Although sensitive to Alzheimer’s disease (AD) pathology, its longitudinal patterns across the clinical AD continuum and prognostic relevance remain unclear. Methods: 577 participants from the DELCODE cohort (>2,100 MRI scans) were analysed: healthy controls individuals (HC, N=202), and patients with subjective cognitive decline (SCD, N=248), mild cognitive impairment (N=93), and AD dementia (N=34). All underwent structural MRI, amyloid (Aβ 42/40 ) and phosphorylated tau181 assessment, and lifestyle-related dementia risk profiling (LIBRA). BAG was derived using brainageR. Associations with baseline cognition, cognitive decline, and clinical progression (up to eight years) were examined using mixed-effects and Cox models. Mediation analyses tested whether BAG accounted for LIBRA-cognition associations. Biomarker-related and clinical findings were replicated in ADNI (N=461). Findings: BAG showed excellent short-term reliability, increased stepwise across the clinical spectrum and was elevated in amyloid-positive SCD, but not in asymptomatic amyloid-positive HC. Longitudinal BAG increases were strongest in amyloid- and tau-positive participants (Aβ+T+). Higher BAG was associated with poorer baseline cognition and predicted cognitive decline, with strongest effects in Aβ+T+. All main findings replicated in ADNI. BAG was associated with LIBRA only in biomarker-negative participants and partly mediated associations with cognitive outcomes in DELCODE. Interpretation: BAG is a reliable non-invasive marker of structural brain health sensitive to AD pathology and to modifiable AD risk. Detectable divergence prior to objective cognitive impairment supports its relevance for early risk stratification and prevention-oriented research. Funding: Helmholtz AI Cooperation Unit (ZT-I-PF-5-163).
- Open Access
- 25 February 2026
- Published by Elsevier in Neuroimage: Reports
- Vol. 6 (1) , 100332
Real-time phase-contrast MRI can be used to quantify cerebrovascular reserve capacity – a comparative study to neurovascular ultrasound in healthy subjects
- 25 February 2026
- Published by Elsevier in Neuroimage: Reports
- Vol. 6 (1) , 100332
Open AccessReal-time phase-contrast MRI can be used to quantify cerebrovascular reserve capacity – a comparative study to neurovascular ultrasound in healthy subjects
- Open Access
- 24 February 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (4) , e214510
Patterns and Trajectories of Behavioral and Neuropsychiatric Symptoms in Frontotemporal Dementia and Primary Progressive Aphasia
Behavioral and neuropsychiatric symptoms are common in frontotemporal dementia (FTD) and primary progressive aphasia (PPA). However, little is known about their patterns, time course, and association with brain atrophy. We, therefore, aimed to describe behavioral and neuropsychiatric phenotypes in patients with FTD and PPA, leveraging a hypothesis-free/data-driven approach. We included participants diagnosed with behavioral variant FTD (bvFTD) or PPA according to Rascovsky and Gorno-Tempini criteria from the German Center for Neurodegenerative Diseases Clinical Registry Study of Neurodegenerative Diseases-FTD prospective multicenter observational cohort study. Symptoms were assessed using the Neuropsychiatric Inventory-Questionnaire. Principal component analysis (PCA) was used to delineate symptom groups. Subsequently, frequency and severity across diagnostic groups were examined. We applied linear mixed-effects models to describe the longitudinal evolution of symptoms. Associations with MRI-assessed atrophy were investigated using linear regression models. A total of 314 patients (42.4% female, mean age 65.52 [SD 9.0] years) with bvFTD or PPA were included. MRI was available for 134 of 314 individuals. PCA revealed 4 natural symptom groups, labeled active behavioral, passive behavioral, affective, and psychotic phenotypes. Symptom groups were observed at comparable frequencies across diagnostic groups. Time from symptom onset (0.130 [0.044-0.217], p < 0.003), sex (1.376 [0.666-2.087], p < 0.001), and the interaction between the nonfluent variant of PPA and sex (-1.940 [-3.242 to -0.638], p = 0.004) showed a significant effect on the active behavioral phenotype, with symptom severity increasing over time and being most pronounced in men with bvFTD. Patients with bvFTD exhibited more severe passive behavioral symptoms compared with any other diagnostic group. For the affective phenotype, a significant interaction between time and sex (0.063 [0.010-0.117], p = 0.021) indicated a progressive increase in symptom severity in men over time. Furthermore, we found robust neuroanatomical correlations of passive behavioral symptoms with subcortical and bilateral frontal and cingulate cortical atrophy. Our findings demonstrate that behavioral and neuropsychiatric symptoms are prevalent in both bvFTD and PPA. Their severity depends on the disease duration, phenotypic group, and sex. This detailed understanding of symptomatology is crucial for optimizing patient care, diagnostic evaluations, and the design of clinical trials. Limitations comprise the lack of neuropathologic validation and the limited availability of MRI data.
- 24 February 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (4) , e214510
Open AccessPatterns and Trajectories of Behavioral and Neuropsychiatric Symptoms in Frontotemporal Dementia and Primary Progressive Aphasia
Behavioral and neuropsychiatric symptoms are common in frontotemporal dementia (FTD) and primary progressive aphasia (PPA). However, little is known about their patterns, time course, and association with brain atrophy. We, therefore, aimed to describe behavioral and neuropsychiatric phenotypes in patients with FTD and PPA, leveraging a hypothesis-free/data-driven approach. We included participants diagnosed with behavioral variant FTD (bvFTD) or PPA according to Rascovsky and Gorno-Tempini criteria from the German Center for Neurodegenerative Diseases Clinical Registry Study of Neurodegenerative Diseases-FTD prospective multicenter observational cohort study. Symptoms were assessed using the Neuropsychiatric Inventory-Questionnaire. Principal component analysis (PCA) was used to delineate symptom groups. Subsequently, frequency and severity across diagnostic groups were examined. We applied linear mixed-effects models to describe the longitudinal evolution of symptoms. Associations with MRI-assessed atrophy were investigated using linear regression models. A total of 314 patients (42.4% female, mean age 65.52 [SD 9.0] years) with bvFTD or PPA were included. MRI was available for 134 of 314 individuals. PCA revealed 4 natural symptom groups, labeled active behavioral, passive behavioral, affective, and psychotic phenotypes. Symptom groups were observed at comparable frequencies across diagnostic groups. Time from symptom onset (0.130 [0.044-0.217], p < 0.003), sex (1.376 [0.666-2.087], p < 0.001), and the interaction between the nonfluent variant of PPA and sex (-1.940 [-3.242 to -0.638], p = 0.004) showed a significant effect on the active behavioral phenotype, with symptom severity increasing over time and being most pronounced in men with bvFTD. Patients with bvFTD exhibited more severe passive behavioral symptoms compared with any other diagnostic group. For the affective phenotype, a significant interaction between time and sex (0.063 [0.010-0.117], p = 0.021) indicated a progressive increase in symptom severity in men over time. Furthermore, we found robust neuroanatomical correlations of passive behavioral symptoms with subcortical and bilateral frontal and cingulate cortical atrophy. Our findings demonstrate that behavioral and neuropsychiatric symptoms are prevalent in both bvFTD and PPA. Their severity depends on the disease duration, phenotypic group, and sex. This detailed understanding of symptomatology is crucial for optimizing patient care, diagnostic evaluations, and the design of clinical trials. Limitations comprise the lack of neuropathologic validation and the limited availability of MRI data.
- Open Access
- 10 December 2025
- Published by Springer Nature in Clinical Neuroradiology
- Vol. 36 (2) , 485-497
Evaluating Unimodal and Multimodal Tracking Strategies for the Reconstruction of Language-related White Matter Tracts
Purpose: Accurate reconstruction of language-related white matter pathways is essential for preoperative planning in brain surgery. While functional (f) MRI activation is often used to guide diffusion (d)MRI tractography, advanced automated protocols rely instead on subcortical anatomical priors. In this study, we evaluate the robustness of anatomically informed protocols without fMRI and compare them with fMRI-guided approaches. Methods: Twenty healthy adults (aged 18–32) underwent fMRI during a language task and dMRI on a 3T MRI scanner. Six language-associated fiber bundles were reconstructed with XTRACT using unimodal and multimodal protocols. Reconstruction similarity was assessed using cross-correlations within-subjects, within-cohort, and across-cohorts. Normalized streamline counts served as a proxy for connectivity, and t -tests were used to quantify differences between tracking protocols. Results: Protocols using anatomically informed subcortical seed and target masks, as well as their combination with functional masks, yielded higher agreement and greater normalized streamline counts than the fMRI-only protocol. The combined approach showed an additional advantage for reconstructing parieto-temporal white matter tracts. Conclusions: These comparisons underscore how protocol choice shapes the reconstruction of language pathways and highlight the need to evaluate these tractography strategies in clinical cohorts.
- 10 December 2025
- Published by Springer Nature in Clinical Neuroradiology
- Vol. 36 (2) , 485-497
Open AccessEvaluating Unimodal and Multimodal Tracking Strategies for the Reconstruction of Language-related White Matter Tracts
Purpose: Accurate reconstruction of language-related white matter pathways is essential for preoperative planning in brain surgery. While functional (f) MRI activation is often used to guide diffusion (d)MRI tractography, advanced automated protocols rely instead on subcortical anatomical priors. In this study, we evaluate the robustness of anatomically informed protocols without fMRI and compare them with fMRI-guided approaches. Methods: Twenty healthy adults (aged 18–32) underwent fMRI during a language task and dMRI on a 3T MRI scanner. Six language-associated fiber bundles were reconstructed with XTRACT using unimodal and multimodal protocols. Reconstruction similarity was assessed using cross-correlations within-subjects, within-cohort, and across-cohorts. Normalized streamline counts served as a proxy for connectivity, and t -tests were used to quantify differences between tracking protocols. Results: Protocols using anatomically informed subcortical seed and target masks, as well as their combination with functional masks, yielded higher agreement and greater normalized streamline counts than the fMRI-only protocol. The combined approach showed an additional advantage for reconstructing parieto-temporal white matter tracts. Conclusions: These comparisons underscore how protocol choice shapes the reconstruction of language pathways and highlight the need to evaluate these tractography strategies in clinical cohorts.
- Open Access
- 14 October 2025
- Published by Genomic Press in Brain Medicine
- Vol. 1 (4) , 62-72
Heart rate modulation and clinical improvement in major depression: A randomized clinical trial with accelerated intermittent theta burst stimulation
Intermittent theta burst stimulation (iTBS) is a promising noninvasive treatment for major depressive disorder (MDD), though significant variability exists in patient responses. This quadruple-blind, sham-controlled crossover randomized clinical trial investigated whether clinical improvement was influenced by the spatial selection of stimulation sites or early cardiac rhythm modulations. Seventy-five patients with MDD (33 women) were randomized to either personalized stimulation sites—identified via the strongest negative functional connectivity between the left dorsolateral prefrontal cortex and the default mode network—or fixed stimulation at the F3 position of the 10–20 EEG system. Electrocardiograms throughout stimulation monitored heart rate and its variability, focusing on heartbeat deceleration heart rate (RR) slope and changes in the root mean square of successive differences between heartbeats (RMSSD). Findings demonstrated that a higher RR slope within the first 45 s of stimulation predicted greater clinical improvement at 6 weeks, while a lower RMSSD change during the first 270 s correlated with improvement at 1 week. However, no significant differences in outcomes were observed between personalized and fixed stimulation sites. This study identified a significant relationship between early heart rhythm modulations and the antidepressant effects of accelerated iTBS in MDD. Although the spatial determination of stimulation sites did not enhance clinical improvement, iTBS-induced changes in cardiac rhythm during early sessions may develop into valuable biomarkers for stratifying patients, enabling more personalized and effective treatment strategies in the future.
- 14 October 2025
- Published by Genomic Press in Brain Medicine
- Vol. 1 (4) , 62-72
Open AccessHeart rate modulation and clinical improvement in major depression: A randomized clinical trial with accelerated intermittent theta burst stimulation
Intermittent theta burst stimulation (iTBS) is a promising noninvasive treatment for major depressive disorder (MDD), though significant variability exists in patient responses. This quadruple-blind, sham-controlled crossover randomized clinical trial investigated whether clinical improvement was influenced by the spatial selection of stimulation sites or early cardiac rhythm modulations. Seventy-five patients with MDD (33 women) were randomized to either personalized stimulation sites—identified via the strongest negative functional connectivity between the left dorsolateral prefrontal cortex and the default mode network—or fixed stimulation at the F3 position of the 10–20 EEG system. Electrocardiograms throughout stimulation monitored heart rate and its variability, focusing on heartbeat deceleration heart rate (RR) slope and changes in the root mean square of successive differences between heartbeats (RMSSD). Findings demonstrated that a higher RR slope within the first 45 s of stimulation predicted greater clinical improvement at 6 weeks, while a lower RMSSD change during the first 270 s correlated with improvement at 1 week. However, no significant differences in outcomes were observed between personalized and fixed stimulation sites. This study identified a significant relationship between early heart rhythm modulations and the antidepressant effects of accelerated iTBS in MDD. Although the spatial determination of stimulation sites did not enhance clinical improvement, iTBS-induced changes in cardiac rhythm during early sessions may develop into valuable biomarkers for stratifying patients, enabling more personalized and effective treatment strategies in the future.
- Open Access
- 17 June 2025
- Published by Elsevier in NeuroImage
- Vol. 317, 121337
Atrial fibrillation reduces CSF flow dynamics. A multimodal MRI study
- 17 June 2025
- Published by Elsevier in NeuroImage
- Vol. 317, 121337
Open AccessAtrial fibrillation reduces CSF flow dynamics. A multimodal MRI study
- Open Access
- 21 April 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 108 (1_suppl) , S258-S273
A computational ontology framework for the synthesis of multi-level pathology reports from brain MRI scans
Background: Convolutional neural network (CNN) based volumetry of MRI data can help differentiate Alzheimer's disease (AD) and the behavioral variant of frontotemporal dementia (bvFTD) as causes of cognitive decline and dementia. However, existing CNN-based MRI volumetry tools lack a structured hierarchical representation of brain anatomy, which would allow for aggregating regional pathological information and automated computational inference. Objective: Develop a computational ontology pipeline for quantifying hierarchical pathological abnormalities and visualize summary charts for brain atrophy findings, aiding differential diagnosis. Methods: Using FastSurfer, we segmented brain regions and measured volume and cortical thickness from MRI scans pooled across multiple cohorts (N = 3433; ADNI, AIBL, DELCODE, DESCRIBE, EDSD, and NIFD), including healthy controls, prodromal and clinical AD cases, and bvFTD cases. Employing the Web Ontology Language (OWL), we built a semantic model encoding hierarchical anatomical information. Additionally, we created summary visualizations based on sunburst plots for visual inspection of the information stored in the ontology. Results: Our computational framework dynamically estimated and aggregated regional pathological deviations across different levels of neuroanatomy abstraction. The disease similarity index derived from the volumetric and cortical thickness deviations achieved an AUC of 0.88 for separating AD and bvFTD, which was also reflected by distinct atrophy profile visualizations. Conclusions: The proposed automated pipeline facilitates visual comparison of atrophy profiles across various disease types and stages. It provides a generalizable computational framework for summarizing pathologic findings, potentially enhancing the physicians’ ability to evaluate brain pathologies robustly and interpretably.
- 21 April 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 108 (1_suppl) , S258-S273
Open AccessA computational ontology framework for the synthesis of multi-level pathology reports from brain MRI scans
Background: Convolutional neural network (CNN) based volumetry of MRI data can help differentiate Alzheimer's disease (AD) and the behavioral variant of frontotemporal dementia (bvFTD) as causes of cognitive decline and dementia. However, existing CNN-based MRI volumetry tools lack a structured hierarchical representation of brain anatomy, which would allow for aggregating regional pathological information and automated computational inference. Objective: Develop a computational ontology pipeline for quantifying hierarchical pathological abnormalities and visualize summary charts for brain atrophy findings, aiding differential diagnosis. Methods: Using FastSurfer, we segmented brain regions and measured volume and cortical thickness from MRI scans pooled across multiple cohorts (N = 3433; ADNI, AIBL, DELCODE, DESCRIBE, EDSD, and NIFD), including healthy controls, prodromal and clinical AD cases, and bvFTD cases. Employing the Web Ontology Language (OWL), we built a semantic model encoding hierarchical anatomical information. Additionally, we created summary visualizations based on sunburst plots for visual inspection of the information stored in the ontology. Results: Our computational framework dynamically estimated and aggregated regional pathological deviations across different levels of neuroanatomy abstraction. The disease similarity index derived from the volumetric and cortical thickness deviations achieved an AUC of 0.88 for separating AD and bvFTD, which was also reflected by distinct atrophy profile visualizations. Conclusions: The proposed automated pipeline facilitates visual comparison of atrophy profiles across various disease types and stages. It provides a generalizable computational framework for summarizing pathologic findings, potentially enhancing the physicians’ ability to evaluate brain pathologies robustly and interpretably.
- Open Access
Disease stage-specific atrophy markers in Alzheimer’s disease
INTRODUCTION: Structural MRI often lacks diagnostic, prognostic, and monitoring value in Alzheimer’s disease (AD), particularly in early disease stages. To improve its utility, we aimed to identify optimal MRI readouts for different use cases. METHODS: We included 363 older adults; healthy controls (HC) who were negative or positive for amyloid-beta (Aβ) and Aβ-positive patients with subjective cognitive decline (SCD), mild cognitive impairment, or dementia of the Alzheimer type. MRI and neuropsychological assessments were administered annually for up to three years. RESULTS: Accelerated atrophy of distinct MTL subregions was evident already during preclinical AD. Symptomatic disease stages most notably differed in their hippocampal and parietal atrophy signatures. Associations of atrophy markers and cognitive inventories varied by intended use and disease stage. DISCUSSION: With the appropriate readout, MRI can detect abnormal atrophy already during preclinical AD. To optimize performance, MRI readouts should be tailored to the targeted disease stage and intended use.
Open AccessDisease stage-specific atrophy markers in Alzheimer’s disease
INTRODUCTION: Structural MRI often lacks diagnostic, prognostic, and monitoring value in Alzheimer’s disease (AD), particularly in early disease stages. To improve its utility, we aimed to identify optimal MRI readouts for different use cases. METHODS: We included 363 older adults; healthy controls (HC) who were negative or positive for amyloid-beta (Aβ) and Aβ-positive patients with subjective cognitive decline (SCD), mild cognitive impairment, or dementia of the Alzheimer type. MRI and neuropsychological assessments were administered annually for up to three years. RESULTS: Accelerated atrophy of distinct MTL subregions was evident already during preclinical AD. Symptomatic disease stages most notably differed in their hippocampal and parietal atrophy signatures. Associations of atrophy markers and cognitive inventories varied by intended use and disease stage. DISCUSSION: With the appropriate readout, MRI can detect abnormal atrophy already during preclinical AD. To optimize performance, MRI readouts should be tailored to the targeted disease stage and intended use.
- Open Access
- 24 April 2024
- Published by Oxford University Press (OUP) in Brain
- Vol. 147 (7) , 2400-2413
A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings
Memory clinic patients are a heterogeneous population representing various aetiologies of pathological aging. It is unknown if divergent spatiotemporal progression patterns of brain atrophy, as previously described in Alzheimer’s disease (AD) patients, are prevalent and clinically meaningful in this group of older adults. To uncover distinct atrophy subtypes, we applied the Subtype and Stage Inference (SuStaIn) algorithm to baseline structural MRI data from 813 participants enrolled in the DELCODE cohort (mean ± SD age = 70.67 ± 6.07 years, 52% females). Participants were cognitively unimpaired (CU; n = 285) or fulfilled diagnostic criteria for subjective cognitive decline (SCD; n = 342), mild cognitive impairment (MCI; n = 118), or dementia of the Alzheimer’s type (n = 68). Atrophy subtypes were compared in baseline demographics, fluid AD biomarker levels, the Preclinical Alzheimer Cognitive Composite (PACC-5), as well as episodic memory and executive functioning. PACC-5 trajectories over up to 240 weeks were examined. To test if baseline atrophy subtype and stage predicted clinical trajectories before manifest cognitive impairment, we analysed PACC-5 trajectories and MCI conversion rates of CU and SCD participants. Limbic-predominant and hippocampal-sparing atrophy subtypes were identified. Limbic-predominant atrophy first affected the medial temporal lobes, followed by further temporal and, finally, the remaining cortical regions. At baseline, this subtype was related to older age, more pathological AD biomarker levels, APOE ε4 carriership, and an amnestic cognitive impairment. Hippocampal-sparing atrophy initially occurred outside the temporal lobe with the medial temporal lobe spared up to advanced atrophy stages. This atrophy pattern also affected individuals with positive AD biomarkers and was associated with more generalised cognitive impairment. Limbic-predominant atrophy, in all and in only unimpaired participants, was linked to more negative longitudinal PACC-5 slopes than observed in participants without or with hippocampal-sparing atrophy and increased the risk of MCI conversion. SuStaIn modelling was repeated in a sample from the Swedish BioFINDER-2 cohort. Highly similar atrophy progression patterns and associated cognitive profiles were identified. Cross-cohort model generalizability, both on the subject and group level, were excellent, indicating reliable performance in previously unseen data. The proposed model is a promising tool for capturing heterogeneity among older adults at early at-risk states for AD in applied settings. The implementation of atrophy subtype- and stage-specific end-points may increase the statistical power of pharmacological trials targeting early AD.
- 24 April 2024
- Published by Oxford University Press (OUP) in Brain
- Vol. 147 (7) , 2400-2413
Open AccessA generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings
Memory clinic patients are a heterogeneous population representing various aetiologies of pathological aging. It is unknown if divergent spatiotemporal progression patterns of brain atrophy, as previously described in Alzheimer’s disease (AD) patients, are prevalent and clinically meaningful in this group of older adults. To uncover distinct atrophy subtypes, we applied the Subtype and Stage Inference (SuStaIn) algorithm to baseline structural MRI data from 813 participants enrolled in the DELCODE cohort (mean ± SD age = 70.67 ± 6.07 years, 52% females). Participants were cognitively unimpaired (CU; n = 285) or fulfilled diagnostic criteria for subjective cognitive decline (SCD; n = 342), mild cognitive impairment (MCI; n = 118), or dementia of the Alzheimer’s type (n = 68). Atrophy subtypes were compared in baseline demographics, fluid AD biomarker levels, the Preclinical Alzheimer Cognitive Composite (PACC-5), as well as episodic memory and executive functioning. PACC-5 trajectories over up to 240 weeks were examined. To test if baseline atrophy subtype and stage predicted clinical trajectories before manifest cognitive impairment, we analysed PACC-5 trajectories and MCI conversion rates of CU and SCD participants. Limbic-predominant and hippocampal-sparing atrophy subtypes were identified. Limbic-predominant atrophy first affected the medial temporal lobes, followed by further temporal and, finally, the remaining cortical regions. At baseline, this subtype was related to older age, more pathological AD biomarker levels, APOE ε4 carriership, and an amnestic cognitive impairment. Hippocampal-sparing atrophy initially occurred outside the temporal lobe with the medial temporal lobe spared up to advanced atrophy stages. This atrophy pattern also affected individuals with positive AD biomarkers and was associated with more generalised cognitive impairment. Limbic-predominant atrophy, in all and in only unimpaired participants, was linked to more negative longitudinal PACC-5 slopes than observed in participants without or with hippocampal-sparing atrophy and increased the risk of MCI conversion. SuStaIn modelling was repeated in a sample from the Swedish BioFINDER-2 cohort. Highly similar atrophy progression patterns and associated cognitive profiles were identified. Cross-cohort model generalizability, both on the subject and group level, were excellent, indicating reliable performance in previously unseen data. The proposed model is a promising tool for capturing heterogeneity among older adults at early at-risk states for AD in applied settings. The implementation of atrophy subtype- and stage-specific end-points may increase the statistical power of pharmacological trials targeting early AD.
- Open Access
Cerebellar Ex Vivo Magnetic Resonance Imaging at its Feasibility Limit: Up to 77-Microns Isotropic Resolution using Low-Bandwidth Balanced Steady State Free Precession (LoBa-bSSFP) Sequences and 3T Standard Equipment
Background Ultra-high-resolution magnetic resonance imaging of the ex vivo brain is increasingly becoming an indispensable tool for studying the morphology and potential pathology of the brain. Despite the important role of the cerebellum in nervous system functions and motor control, as well as its potential damage in neurological diseases, it remains relatively understudied compared to other brain regions. One major reason is the even finer structures. Methods A balanced steady state free precession approach with receiver bandwidths as low as 50Hz/pixel and long repetition times of 36ms is suggested and optimized, called “LoBa-bSSFP”, which enhances the signal-to-noise ratio and alleviates strain on the gradient system for the ultra-high spatial resolutions. A radiofrequency phase cycle scheme is used to reduce potential artifacts. Only 3T MRI standard equipment is utilized for acquisition and basic image reconstruction of the ex vivo brain immersed in perfluoropolyether. Results The presented LoBa-bSSFP approach provides images with very good soft tissue contrast and a detailed visualization of cerebellar morphology. It enables isotropic resolutions of 98-microns for the entire cerebellum, a further refinement allows even up to 77-microns isotropic on a purely clinical MR system. The acquisitions preserved the integrity of the ex vivo cerebellum, so maintaining its connection to the cerebrum and brainstem. Conclusions Our findings demonstrate the feasibility of employing 3T based LoBa-bSSFP for true ultra-high-resolution ex vivo imaging of the cerebellum, reaching resolutions up to 77-microns isotropic and the potential to reveal subtle microscopic abnormalities of the cerebellar cortex. LoBa-bSSFP may be superior to conventional FLASH sequences in terms of acquisition efficiency and - in some cases - even contrast.
Open AccessCerebellar Ex Vivo Magnetic Resonance Imaging at its Feasibility Limit: Up to 77-Microns Isotropic Resolution using Low-Bandwidth Balanced Steady State Free Precession (LoBa-bSSFP) Sequences and 3T Standard Equipment
Background Ultra-high-resolution magnetic resonance imaging of the ex vivo brain is increasingly becoming an indispensable tool for studying the morphology and potential pathology of the brain. Despite the important role of the cerebellum in nervous system functions and motor control, as well as its potential damage in neurological diseases, it remains relatively understudied compared to other brain regions. One major reason is the even finer structures. Methods A balanced steady state free precession approach with receiver bandwidths as low as 50Hz/pixel and long repetition times of 36ms is suggested and optimized, called “LoBa-bSSFP”, which enhances the signal-to-noise ratio and alleviates strain on the gradient system for the ultra-high spatial resolutions. A radiofrequency phase cycle scheme is used to reduce potential artifacts. Only 3T MRI standard equipment is utilized for acquisition and basic image reconstruction of the ex vivo brain immersed in perfluoropolyether. Results The presented LoBa-bSSFP approach provides images with very good soft tissue contrast and a detailed visualization of cerebellar morphology. It enables isotropic resolutions of 98-microns for the entire cerebellum, a further refinement allows even up to 77-microns isotropic on a purely clinical MR system. The acquisitions preserved the integrity of the ex vivo cerebellum, so maintaining its connection to the cerebrum and brainstem. Conclusions Our findings demonstrate the feasibility of employing 3T based LoBa-bSSFP for true ultra-high-resolution ex vivo imaging of the cerebellum, reaching resolutions up to 77-microns isotropic and the potential to reveal subtle microscopic abnormalities of the cerebellar cortex. LoBa-bSSFP may be superior to conventional FLASH sequences in terms of acquisition efficiency and - in some cases - even contrast.